Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
24/7 Wall St. Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with revenue up 3.4% to $4.48B. AUSTEDO surged 38% to $618M and drove the innovative portfolio expansion. Teva crushed EPS estimates by … Read more